

INTERNATIONAL SPACE STATION NATIONAL LABORATORY: THE NEXT DECADE OF RESULTS

Ray Lugo, Chief Executive Officer, Michael Roberts, PhD, Chief Scientist

Briefing for the Decadal Survey on Biological and Physical Sciences Research in Space 2023-2032

Meeting #5 4 May 2022




ISS NATIONAL LAB MISSION


To manage the ISS National Lab as a public service for R&D to benefit the U.S. taxpayer and to foster a scalable and sustainable low Earth orbit economy.

We leverage our core competencies, facilitate public-private partnerships, and utilize the platform capabilities and unique operating environment of the space station.

We create demand, incubate in-space business ventures, provide access for and awareness of discovery science and technological innovation, and promote science literacy of the future workforce.



NASA MISSION: THE ACQUISITION OF COMMERCIAL LEO DESTINATIONS (CLDs)




4

Source: NASA

NASA MISSION: ACCESS TO LEO

\$54.5K SPACE SHUTTLE 1981

Cost to Launch Payloads to Low Earth Orbit



FEBRUARY-2020



DECEMBER-2021







NASA Selects First Commercial Destination Module for ISS

NASA awarded **Axiom Space** a firm-fixed price, IDIQ contract with a maximum value of up to **\$140M** over an up to seven-year period. In addition, the Ax-1 private astronaut mission launched to ISS April 8, 2022 and a 2nd PAM was awarded to Axiom for 2023.

NASA Selects 3 Companies to Develop Commercial LEO Destinations in Space

The largest award, \$160M, went to the Nanoracks team including Voyager Space and Lockheed Martin. The team announced a space station concept called *Starlab* October 21 that could be ready as soon as 2027.

A 2nd award, valued at \$130M, went to a **Blue Origin** team for the *Orbital Reef* space station concept announced Oct 25. The team includes Boeing, Redwire and Sierra Space, among others, with a goal of entering initial operations in the latter half of the 2020s.

The 3rd award, worth \$125.6M, went to a **Northrop Grumman** concept based on the (1) Cygnus CRS spacecraft, (2) Mission Extension Vehicle satellite servicing program, and (3) Habitation and Logistics Outpost (HALO) module it is building for NASA's lunar Gateway.

\$555M

NASA MISSION: TRANSITION FROM ISS




Biden-Harris Administration Extends Space Station Operations Through 2030

Brian Dunbar December 31, 202 Uncategorized



The space station is viewed from the SpaceX Cargo Dragon during its automated approach before docking. Credit: NASA TV

NASA Administrator Bill Nelson announced today the Biden-Harris Administration's commitment to extend International Space Station (ISS) operations through 2030, and to work with our international partners in Europe (ESA, European Space Agency), Japan (JAXA, Japan Aerospace Exploration Agency), Canada (CSA, Canadian Space Agency), and Russia (State Space Corporation Roscosmos) to enable continuation of the groundbreaking research being conducted in this unique orbiting laboratory through the rest of this decade.




RECENT POSTS

- Cosmonauts Prep for Spacewalk as Astronauts Work Science and Maintenance
- Dragon, Spacewalk Preps Amidst Space Botany and Biology Research
- Crew Starts Week with Space Agriculture, Human Cells and Spacesuits
- Biology, Agriculture Studies as Astronaut Begins Record-Breaking Spree
- Space Biology, Science Hardware Work Keeping Station Crew Busy

RECENT COMMENTS

- Siphelele charles mntungwa on Space Biology, Science Hardware Work Keeping Station Crew Busy
- Mark Garcia on Last Week of 2021 Sees New Space Research Kick Off
- Mark Garcia on Dragon Checks, Biology and Spacewalk Preps Fill Crew Day
- Mark Garcia on Crew Kicks off 2022 with Biology, Botany and Spacewalk Preps
- Nazia on Dragon Checks, Biology and Spacewalk Preps Fill Crew Day

ARCHIVES




International Space Station Transition Report

pursuant to Section 303(c)(2) of the NASA Transition Authorization Act of 2017 (P.L. 115-10)

January 2022

https://www.nasa.gov/feature/nasa-providesupdated-international-space-station-transition-plan






DEMAND CREATION: FUNDAMENTAL SCIENCE ON ISS FUNDED* BY OTHERS

ISS National Lab funding Other Government Agency funding Public:Private fundina 2022 2013... 2016 2017 2018 2019 2020 2021 \$1M ISSNL \$1M IISSNL Organs-On-Chips **Stem Cell** NSF \$1.5M NSF \$1.8M NSF \$2.0M **NSF** \$2.2M NSF \$3.0M NSF \$3.6M **NSF** \$3.6M Combustion Fluid Dynamics **Transport Transport Transport Transport Transport Phenomena** Phenomena Phenomena Phenomena **Phenomena** NSF \$0.6M NSF \$4.0M NSF ~\$1.2M NSF \$2.0M NSF \$1.6M Tissue Eng. and Tissue Eng. and **Tissue** Tissue Eng. and Tissue Eng. and Mechanobiol. **Engineering** Mechanobiol. Mechanobiol. Mechanobiol. National Center NIH \$12M NIH \$11M for Advancing Translational Sciences Chips In Space Chips In Space National Institute of Biomedical Imaging and Bioengineering NASA \$0.5M ISSNL awarded \$250k to the winning team and the NASA STMD Centennial Methuselah Foundation, by agreement with CASIS, Centennial Vascular Tissue Challenae awarded \$250k to the runner-up team to conduct a Challenge (VTC) ISS NATIONAL LABORATORY technology demonstration flight to the ISS by 2024.

DEMAND CREATION: ISS NATIONAL LAB COMMERCIAL FACILITIES



Aegis Aerospace Inc.

BioServe Space Technologies

Craig Technologies

Hnu Photonics, LLC

Lamont Aerospace

Nanoracks, LLC

OmniTeq, LLC

ProXops, LLC

Redwire Space

Rhodium Scientific

Space Tango, Inc.

STa ARS

Techshot, Inc.

Teledyne Brown Engineering, Inc.


10


VALUE CREATION: BIOMANUFACTURING IN SPACE WORKSHOP

The ISS is a unique laboratory in LEO with capabilities to advance stem cell research, disease modeling, tissue engineering, regenerative medicine, and biofabrication.

The workshop seeks to **identify the most innovative scientific approaches in biomanufacturing enabled by LEO** that can enable the development and translation of therapeutics and interventions for terrestrial use as well as the steps needed to validate that the technologies are clinically ready and economically viable.

Technical areas of primary interest are stem cells, organoids, microphysiological systems, and biofabrication - collectively termed biomanufacturing here - and how Al/automation can be integrated in orbit to improve iteration and throughput to enhance their development for clinical and manufacturing applications on Earth.









VALUE CREATION: STAKEHOLDER WORKSHOPS

ISS National Lab has supported stem cell research, drug discovery, and medical device technology development since 2013

NIH and NSF co-sponsor annual MPS/organoid payloads

The ISS has multiple biofabrication facilities

VALUE CREATION: ROADMAPS TO THE FUTURE

Opportunities for Biomanufacturing in Low Earth Orbit: Current Status and Future Directions

https://www.preprints.org/manuscript/202108.0044/v1

Biomanufacturing in Low Earth Orbit for Regenerative Medicine

https://doi.org/10.1016/j.stemcr.2021.12.001



I. CLINICAL APPLICATIONS OF SPACE-ENABLED R&D

Atrophy is a process involving the breakdown and loss of tissue. Aging is one example of progressive tissue degeneration, whereby muscle mass declines up to 2% a year after age 50, while bone loss occurs at an average rate of 3-5% per decade.

Targeting the myostatin/activin A signaling pathway had significant beneficial effects in protecting against both muscle and bone loss in microgravity.

Targeting myostatin/activin A protects against skeletal muscle and bone loss during spaceflight

Se-Jin Lee^{a,b,1}, Adam Lehar^a, Jessica U. Meir^c, Christina Koch^c, Andrew Morgan^c, Lara E. Warren^d, Renata Rydzik^e, Daniel W. Youngstrom^e, Harshpreet Chandok^a, Joshy George^a, Joseph Gogain^f, Michael Michaud^a, Thomas A. Stoklasek^a, Yewei Liu^a, and Emily L. Germain-Lee^{g,h}

^aThe Jackson Laboratory for Genomic Medicine, Farmington, CT 06032; ^bDepartment of Genetics and Genome Sciences, University of Connecticut School of Medicine, Farmington, CT 06030; ^cThe National Aeronautics and Space Administration, NASA Johnson Space Center, Houston, TX 77058; ^dCenter for the Advancement of Science in Space, Houston, TX 77058; ^eDepartment of Orthopaedic Surgery, University of Connecticut School of Medicine, Farmington, CT 06030; ^eSomaLogic, Inc., Boulder, CO 80301; ^eDepartment of Pediatrics, University of Connecticut School of Medicine, Farmington, CT 06030; and ^eConnecticut Children's Center for Rare Bone Disorders, Farmington, CT 06032


Contributed by Se-Jin Lee, August 4, 2020 (sent for review July 14, 2020; reviewed by Shalender Bhasin and Paul Gregorevic)

Among the physiological consequences of extended spaceflight are loss of skeletal muscle and bone mass. One signaling pathway that plays an important role in maintaining muscle and bone homeostasis is that regulated by the secreted signaling proteins, myostatin (MSTN) and activin A. Here, we used both genetic and pharmacological approaches to investigate the effect of targeting MSTN/activin A signaling in mice that were sent to the International Space Station. Wild type mice lost significant muscle and bone mass during the 33 d spent in microgravity. Muscle weights

signaling and, as a result, can induce significant muscle growth when given systemically to *wild type* mice (13). Indeed, by blocking both ligands, this decoy receptor can induce significantly more muscle growth than other MSTN inhibitors, and at high doses, ACVR2B/Fc can induce over 50% muscle growth in just 2 wk

Moreover, because this decoy receptor can block not only MSTN but also activin A, systemic administration of ACVR2B/ Fc can also lead to significant increases in bone density (18–20).


EXAMPLES OF VALUE CREATION LEADING TO SCIENTIFIC DISCOVERY AND INNOVATION



II. INDUSTRIAL AND CLINICAL APPLICATIONS OF SPACE-ENABLED R&D

LambdaVision, an innovative biomedical startup, has leveraged ISS National Lab resources for in-space production applications to improve manufacturing of the company's artificial retina to restore vision in those blinded by retinal degenerative diseases. A series of investigations in partnership with ISS National Lab Commercial Service Provider Space Tango are improving the quality of the artificial retina by limiting imperfections that occur during 15 manufacturing on Earth.

III. INDUSTRIAL AND CLINICAL APPLICATIONS OF SPACE-ENABLED R&D



UV imaging of a ground control sample (L) and spaceflight sample (R).

Merck & Company's Keytruda® crystal investigation, showing the more uniform size and distribution of crystals grown in microgravity. Keytruda®, a cancer immunotherapy drug, is one of Merck & Co.'s top selling products.

THE ISS NATIONAL LAB AS A CATALYST FOR SCIENTIFIC INNOVATION

15 April 2022

NASA selects eight proposals submitted in response to a NASA Research Announcement seeking In Space Production Applications (InSPA) flight demonstrations on the ISS National Lab. The selected proposals have a total award value of up to \$21M through FY2025.



Apr 15, 2022

NASA Selects Proposals to Enable Manufacturing In Space for Earth



Following a decade of assembly of the International Space Station and the subsequent decade of research onboard the ISS National Lab, NASA moves boldly into the decade of results with the award of new and promising technologies for in-space manufacturing of advanced materials and products for use on Earth. With more than 21 years of continuous occupation, the International Space was the product to the development of new technologies and products that have the potential to improve the quality of life on Earth.

Decades of microgravity research have laid the foundation for U.S. industry to demonstrate the unique market value of in-space manufacturing, technology advancement, and drug development with the help of NASA's investment in dedicated transportation and research time for ISS National Laboratory investigations. To date, NASA has provided seed money in excess of \$38 million for more than a dozen technologies to enable innovative companies to mature their concepts and stimulate demand for future markets. The awards are a key element of NASA's goal to develop a robust economy in low-Earth orbit where NASA will be one of many customers.

BIOMATERIALS

- Biomanufacturing of Drug-Delivery Medical Devices, Auxilium Biotechnologies, Inc., San Diego, CA
- Expansion of Hematopoietic Stem Cells for Clinical Application, BioServe Space Technologies and the University of Colorado, Boulder, CO
- Establishing Production of Stem Cell Therapies, Cedars-Sinai Regenerative Medicine Institute, Los Angeles, CA
- Volumetric Additive Manufacturing for Organ Production, Lawrence Livermore National Laboratory, Livermore, CA
- Pharmaceutical In-space Laboratory (PIL), , Redwire Corporation Inc., Greenville, IN
- Biomimetic Fabrication of Multifunctional DNA-inspired Nanomaterials, University of Connecticut, Storrs, CT

ADVANCED MATERIALS

- Fabrication of Flawless Glass in Microgravity, Flawless Photonics, Inc., Los Altos Hills, CA
- Semimetal-Semiconductor Composite Bulk Crystals, United Semiconductors, LLC, Los Alamitos, CA

THE ISS NATIONAL LAB AS A CATALYST FOR SCIENTIFIC INNOVATION

1 March 2022

4 Agencies Select 8 Research Projects to Extend Longevity of 3D Tissue Chips to 6 Months NASA-SMD, FDA, NIH, and the Department of Health and Human Services Biomedical Advanced Research and Development Authority (BARDA), announce the award of 8 contracts in a multi-agency collaboration that will extend tissue viability and physiological function to a minimum of 6 months using automated engineering capabilities for real-time online readouts in complex human in vitro models, such as tissue chips or microphysiological systems. The selected studies aim to fund the development and validation of tissue chips which can function successfully for 6 months or longer in an automated fashion, to be used for modeling of acute and/or chronic exposures (e.g., to drugs and other compounds, radiation, environmental hazards, infection, microgravity exposure, etc.). When fully implemented, approximately \$16M will be awarded in fiscal years 2022-2025.

- Elizabeth Blaber, Rensselaer Polytechnic Institute, *Understanding the Brain-Liver-Gut Axis during Spaceflight and Aging*
- Joel Blanchard, ICAHN School of Medicine at Mount Sinai, Identification of Biomarkers and Pathological Mechanisms via Longitudinal Analysis of Neurological and Cerebrovascular Responses to Neurotoxic Stress Using a Multi-cellular Integrated Model of the Human Brain
- Guohao Dai, Northeastern University, Bioengineer Long-lasting 3D Neurovascular Microphysiological System to Model Chronic Inflammation-mediated Neurodegeneration
- Abhishek Jain, Texas A&M, Long-term Patient iPSC Vessel Chip Model to Assess Stressors of Atherosclerosis and mRNA Therapeutics
- Christopher Porada, Wake Forest University, Long-lived Single- and Multi-organ Tissue Equivalent (OTE) Platforms to Model the Response of Human Tissues to Various Stressors
- Gordana Vunjak-Novakovic, Columbia University, MORPH: Multi-Organ Repair Post Hypoxia
- Joseph Wu, Stanford University, Assessing Long-Term Effects of Radiation Exposure in Engineered Heart & Vascular Tissues
- Catherine Yeung, University of Washington, Extended Culture of Kidney MPS and Organoids to Model Acute and Chronic Exposure to Drugs and Environmental Toxins

THE ISS NATIONAL LAB AS A CATALYST FOR SCIENTIFIC INNOVATION

Axiom Space Establishes a Winston-Salem Presence in the Regenerative Medicine Hub Published April 19th, 2022



ISSNL awarded \$250k to the winning team and the Methuselah Foundation, by agreement with CASIS, awarded \$250k to the runner-up team to conduct a technology demonstration flight to the ISS by 2024.

Partnership with WFIRM and ReMDO will Pioneer Biomanufacturing in Space

Regenerative medicine manufacturing in space is the next frontier and will be possible due to a new three-way partnership between Axiom Space, which is building the world's first commercial space station, the RegenMed Development Organization (ReMDO), the first organization dedicated to advancing regenerative medicine manufacturing scale-up and automation, and the Wake Forest Institute of Regenerative Medicine (WFIRM), an international leader in translating scientific discovery into clinical therapies.




AVOIDING A TRAGEDY OF THE COMMONS

"I didn't know we had a National Lab. I thought we were an autonomous collective."

Top image and misquote courtesy of **Monty Python and The Holy Grail** (1975).


Bottom image from Figure 29.2, Environmental Science for AP[®], 2nd Ed. © 2015 W.H. Freeman and Co.






Use of the commons is below the carrying capacity of the land. All users benefit. If one or more users increase the use of the commons beyond its carrying capacity, the commons becomes degraded. The cost of the degradation is incurred by all users. Unless environmental costs are accounted for and addressed in land use practices, eventually the land will be unable to support the activity.

AVOIDING A TRAGEDY OF THE COMMONS






Bryce Briefing: Global Orbital Space Launches Q1 2022

Images courtesy of BryceTech: https://brycetech.com/briefing



ISS NATIONAL LAB PATHWAYS

The Launch



On-orbit Operations

Postflight

ISS NATIONAL LAB PORTFOLIO

FUNDAMENTAL SCIENCE







TECHNOLOGY DEVELOPMENT



STEM ENGAGEMENT



InSPA: IN-SPACE PRODUCTION APPLICATIONS










ISS NATIONAL LAB EXTERNAL FUNDING CUMULATIVE, ALL TIME



ISS NATIONAL LAB PORTFOLIO

\$419M

188
ACADEMIC, NONPROFIT, &
NON-NASA GOVERNMENT
AGENCY PROJECTS
Emory, MIT, MJFF, ORNL, et al

197
INDUSTRY PROJECTS
AstraZeneca, Delta Faucet,
Goodyear, Merck, Novartis,
Procter Gamble, et al

14 COMMERCIAL SERVICE PROVIDERS

Aegis Aerospace, Axiom Space, BioServe, Nanoracks, Redwire, Sierra Space, Space Tango, et al


23 COMMERCIAL IMPLEMENTATION PARTNERS

Bionetics, Felix & Paul, Leidos Innovations, Rhodium Scientific, SEOPS, Teledyne Brown Engineering, et al

INDUSTRY FUNDING PARTNERS

Apple, Boeing, Estee Lauder, Target, et al 260 MEMBER INVESTOR NETWORK

GOVERNMENT
AGENCY FUNDING
PARTNERS
Dod, NSF, NIH, et al



ISS NATIONAL LAB: PROGNOSTICATION 2012 2021 2030 (Goals)

	A COLUMN TO THE PARTY OF THE PA	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	
Projects	5	334	+008
Payloads		538	1,250+
IPs/CSPs	21/3	39/14	60+/28+
Commercial Facilities	3	18	40+
Investor Network Members	0	245	500+
NASA + External Funding (incl. OGAs + Commercial)	\$15M	\$394M	\$985M
Start-Up Capital Raised (Post Flight, Cumulative)	0	\$1.1B+	\$2.75B

Register Now ● Last Day for Early Bird Pricing is May 27



https://www.issconference.org/

https://www.issconference.org/



WORKSHOP: LEVERAGING THE MICROGRAVITY ENVIRONMENT FOR IN-SPACE PRODUCTION

In 2020, the Center for the Advancement of Science in Space, Inc. (CASIS), manager of the ISS National Lab, and the University of Pittsburgh's McGowan Institute for Regenerative Medicine hosted a Biomanufacturing in Space Symposium. In a series of virtual working sessions, the symposium gathered thought leaders in the areas of tissue engineering, regenerative medicine, and space-based research to identify the most promising oportunities to leverage the ISS for research and technology development to advance space-based biomanufacturing. The symposium was meant to serve as the first step in developing a roadmap to establish a robust and sustainable market for biomanufacturing in space. A perspective paper discussing the goals and outcomes of the symposium was supulsihed in Preprints. Additionally, a peer-reviewed version of the perspective paper was published in Stem Cell Reports. Since then, CASIS and NASA have worked to issue several funding opportunities based, in part, on the outcomes from the symposium. During this workshop, we will discuss the results of the previous symposium; address the work done by CASIS, NASA, and others since; and solicit feedback on next steps.

DIRLIC MEETING: ISS NATIONAL LARODATODY LISED ADVISORY COMMITTEE

The ISS National Laboratory User Advisory Committee (UAC) provides CASIS with user input and perspective about the management of ISS National Lab resources. Conference registrants are invited to attend the UAC meeting to hear the latest updates and provide feedback to the committee.

Meeting Date and Time: Monday, July 25, 2:30 p.m. ET

EVENT: WOMEN'S NETWORKING BREAKFAST

Breakfast Date and Time: Thursday, July 28, 7:15 a.m. ET

Start your conference day with coffee, a light breakfast, and a lively speed-networking session. Share your experiences with other women in aerospace who are making big and bold impacts across the industry. Join us for a fun morning session with inspirational women.



ISS NATIONAL LABORATORY® THANK YOU

www.ISSNationalLab.org



ISS National Lab



ISS_CASIS



in ISS National Lab



ISSNationalLab



In the 1960s, our nation set forth on a voyage of discovery to the moon... and rediscovered our planet.

Image courtesy of NASA.



In the 1980s, our nation joined with other nations to start humans on a course to continuously live and work in space... and rediscovered ourselves.

Image courtesy of NASA.



In the 2020s, where will our imaginations and voyages to scientific discovery take us?

Image courtesy of NASA.